Media

Updated results from phase 3 OCEAN study shows melflufen met primary endpoint of superior PFS – Overall Survival data lead to partial clinical hold

Adcendo Appoints Michael Pehl as Chief Executive Officer

Nordic Nanovector Appoints Malene Brondberg as Interim Chief Executive Officer

Spruce Biosciences Appoints Renowned Drug Developer Kirk Ways, M.D., Ph.D. to Board of Directors

InCarda Therapeutics Announces Positive End-of-Phase 2 Meeting with FDA for InRhythm™ for Treatment of Atrial Fibrillation

Nordic Nanovector Announces Initial Results from LYMRIT 37-05 Phase 1 Trial of Betalutin® in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Spruce Biosciences Announces Publication of Phase 2 Results for Tildacerfont in Journal of Clinical Endocrinology and Metabolism

Doctrin raises €13 million to accelerate international expansion